| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
IN8bio, Inc.
13D/A
INAB · 45674E109
|
4.0% |
12/29/2025
Event 12/22/2025
|
||||
| BIOS Fund II, LP | 0.2% | |||||
| BIOS Fund II QP, LP | 0.6% | |||||
| BIOS Fund II NT, LP | 0.1% | |||||
| BIOS Incysus Co-Invest I, LP | 0.3% | |||||
| BIOS Fund III, LP | 0.2% | |||||
| BIOS Fund III QP, LP | 1.3% | |||||
| BIOS Fund III NT, LP | 0.2% | |||||
| Bios Clinical Opportunity Fund, LP | 1.1% | |||||
| BP Directors, LP | 0% | |||||
| Bios Equity Partners, LP | 0% | |||||
| Bios Equity Partners II, LP | 1.3% | |||||
| BIOS Equity Partners III, LP | 1.7% | |||||
| Bios Equity COF, LP | 1.1% | |||||
| Cavu Management, LP | 2.9% | |||||
| BIOS Capital Management, LP | 4.0% | |||||
| Cavu Advisors, LLC | 2.9% | |||||
| BIOS Advisors GP, LLC | 4.0% | |||||
| Kreis Leslie W. | 2.9% | |||||
| Fletcher Aaron G.L. | 4.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.